Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
Purpose
The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.
Condition
- Lung Cancer
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy - ECOG performance status of 0-2 - Age ≥ 18 years old - Ability to understand and the willingness to personally sign the written IRB approved informed consent document - Estimated life expectancy of 12 weeks or longer
Exclusion Criteria
- Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist - Age < 18 years old - Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree - Diagnosis of interstitial pulmonary fibrosis - Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields
Study Design
- Phase
- Phase 1
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Hypofractionated accelerated radiation therapy (HART) |
Patients will either be treated with 60-66 Gy in 30, 25, or 20 fractions based on ability to meet constraints to key organs at risk |
|
Recruiting Locations
Stanford University
Palo Alto, California 94305
Palo Alto, California 94305
Stanford Cancer Center South Bay
San Jose, California 95124
San Jose, California 95124
More Details
- Status
- Recruiting
- Sponsor
- Stanford University